Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
106 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Actavis plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Actavis plc - Product Pipeline Review - 2014', provides an overview of the Actavis plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Actavis plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Actavis plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Actavis plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Actavis plc's pipeline products Reasons to buy - Evaluate Actavis plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Actavis plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Actavis plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Actavis plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Actavis plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Actavis plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Actavis plc Snapshot 7 Actavis plc Overview 7 Key Information 7 Key Facts 7 Actavis plc- Research and Development Overview 8 Key Therapeutic Areas 8 Actavis plc- Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products- Monotherapy 12 Pipeline Products- Combination Treatment Modalities 13 Pipeline Products- Partnered Products 14 Partnered Products/Combination Treatment Modalities 15 Actavis plc- Pipeline Products Glance 17 Actavis plc- Late Stage Pipeline Products 17 Pre-Registration Products/Combination Treatment Modalities 17 Filing rejected/Withdrawn Products/Combination Treatment Modalities 18 Phase III Products/Combination Treatment Modalities 19 Actavis plc- Clinical Stage Pipeline Products 20 Phase II Products/Combination Treatment Modalities 20 Phase I Products/Combination Treatment Modalities 21 Actavis plc- Early Stage Pipeline Products 22 IND/CTA Filed Products/Combination Treatment Modalities 22 Discovery Products/Combination Treatment Modalities 23 Actavis plc- Drug Profiles 24 (ceftazidime + avibactam) 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 (memantine hydrochloride ER + donepezil hydrochloride) 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 APT-1026 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 dalbavancin 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 (nebivolol + valsartan) 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 cariprazine 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 norethindrone 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 (aclidinium bromide + formoterol fumarate) 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 estradiol acetate 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 follitropin alfa 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 pancrelipase DR 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 udenafil 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ulipristal acetate 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 WC-2055 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 (ceftaroline fosamil + avibactam) 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 (estrogen + progesterone) 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 albaconazole 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 cebranopadol 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 memantine hydrochloride 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 oxybutynin hydrochloride 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 sarecycline 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 EUR-1100 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Progesterone Vaginal Gel Second Generation 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 bezafibrate ER 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Actavis plc- Pipeline Analysis 62 Actavis plc- Pipeline Products by Target 62 Actavis plc- Pipeline Products by Route of Administration 64 Actavis plc- Pipeline Products by Molecule Type 65 Actavis plc- Pipeline Products by Mechanism of Action 66 Actavis plc- Recent Pipeline Updates 68 Actavis plc- Dormant Projects 90 Actavis plc - Discontinued Pipeline Products 92 Discontinued Pipeline Product Profiles 92 alvameline maleate 92 dexloxiglumide 92 ME-1036 92 neramexane mesylate 92 oglemilast 93 radiprodil 93 Actavis plc- Company Statement 94 Actavis plc- Locations And Subsidiaries 99 Head Office 99 Other Locations & Subsidiaries 99 Appendix 105 Methodology 105 Coverage 105 Secondary Research 105 Primary Research 105 Expert Panel Validation 105 Contact Us 106 Disclaimer 106
List of Tables Actavis plc, Key Information 7 Actavis plc, Key Facts 7 Actavis plc- Pipeline by Indication, 2014 9 Actavis plc- Pipeline by Stage of Development, 2014 11 Actavis plc- Monotherapy Products in Pipeline, 2014 12 Actavis plc- Combination Treatment Modalities in Pipeline, 2014 13 Actavis plc- Partnered Products in Pipeline, 2014 14 Actavis plc- Partnered Products/ Combination Treatment Modalities, 2014 15 Actavis plc- Pre-Registration, 2014 17 Actavis plc- Filing rejected/Withdrawn, 2014 18 Actavis plc- Phase III, 2014 19 Actavis plc- Phase II, 2014 20 Actavis plc- Phase I, 2014 21 Actavis plc- IND/CTA Filed, 2014 22 Actavis plc- Discovery, 2014 23 Actavis plc- Pipeline by Target, 2014 62 Actavis plc- Pipeline by Route of Administration, 2014 64 Actavis plc- Pipeline by Molecule Type, 2014 65 Actavis plc- Pipeline Products by Mechanism of Action, 2014 66 Actavis plc- Recent Pipeline Updates, 2014 68 Actavis plc- Dormant Developmental Projects,2014 90 Actavis plc - Discontinued Pipeline Products, 2014 92 Actavis plc, Subsidiaries 99
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
